Table 1.
Characteristics of the CAD Population
| Characteristics | n = 82 |
|---|---|
| Age, yrs | 62.0 ± 9.7 |
| > 65 | 33 (40.2) |
| Gender | |
| Male | 67 (81.7) |
| Female | 15 (18.3) |
| BMI, kg/m2 | 27.8 ± 4.1 |
| BMI < 25 | 21 (25.6) |
| BMI ≥25 to < 30 | 40 (48.8) |
| BMI ≥30 | 21 (25.6) |
| Lifestyle | |
| Smoking | |
| Never | 37 (45.1) |
| Former | 38 (46.3) |
| Current | 7 (8.6) |
| Alcohol users | 32 (39.0) |
| Exercisers | 50 (61.0) |
| Medical history | |
| Cardiovascular disease | |
| Myocardial infarction | 32 (39.0) |
| Percutaneous transluminal coronary intervention | 61 (74.4) |
| Coronary artery bypass surgery | 23 (28.4) |
| Stroke/transient ischemic attack | 3 (3.7) |
| Peripheral artery disease | 4 (4.9) |
| Family history of cardiovascular disease | 48 (58.5) |
| Hypertension | 59 (72.0) |
| Duration of hypertension, months | 133.9 ± 119.4 |
| Diabetes | 31 (37.8) |
| Type I diabetes | 3 (3.7) |
| Type II diabetes | 28 (34.1) |
| Duration of diabetes, yrs | 12.5 ± 15.0 |
| Fasting glucose, mmol/l | 6.0 ± 1.5 |
| Medication | |
| Statin | 78 (95.1) |
| Duration, months | 55.5 ± 73.5 |
| Beta-blocker | 50 (61.0) |
| Calcium-channel blockers | 13 (15.9) |
| ACE inhibitors | 32 (39.0) |
| AT II blockers | 10 (12.2) |
| Nitrates | 9 (11.0) |
| Diuretics | 13 (15.9) |
| Aspirin | 75 (91.5) |
| Clopidrogrel | 60 (73.2) |
| Insulin | 6 (7.3) |
| Oral antidiabetics (metformin and/or others) | 26 (31.7) |
| FDG-PET/CT | n = 79 |
| Blood pool activity (left and right jugular vein; SUVmean) | 1.08 ± 0.1 |
| wholevesselTBRmax | 2.0 ± 0.3 |
| wholevesselTBRmax > 1.8 | 55 (69.6) |
| wholevesselTBRmax > 2.0 | 32 (40.5) |
| wholevesselTBRmax > 2.2 | 19 (24.1) |
| wholevesselTBRmax > 2.4 | 10 (12.7) |
| wholevesselSUVmax | 2.14 ± 0.4 |
| Single hottest segment | 2.32 ± 0.4 |
| Percent active segments | 56.3 ± 37.7 |
| 0% | 10 (12.7) |
| 1%–30% | 16 (20.2) |
| 31%–60% | 18 (22.8) |
| 61%–90% | 8 (10.2) |
| 91%–100% | 27 (34.2) |
Values are mean ± SD or n (%). Percent active segments is defined as the percentage of segments with TBRmax > 1.9.
ACE = angiotensin-converting enzyme; AT II = angiotensin II; BMI = body mass index; CAD = coronary artery disease; FDG-PET/CT = 18F-fluorodeoxyglucose positron emission tomography/computed tomography; SUVmax = maximum standardized uptake value; TBRmax = maximum target-to-background ratio.